Ceftriaxone

Ceftriaxone is a third-generation cephalosporin antibiotic that kills susceptible bacteria by disrupting bacterial cell-wall synthesis. Its broad activity and long half-life support once-daily dosing for many infections.

Beta-lactam antibiotics: A family of antibiotics that inhibit bacterial cell-wall synthesis through beta-lactam rings. Ceftriaxone belongs to this family and shares its cell-wall target.
Bacterial meningitis: An infection of the membranes surrounding the brain and spinal cord caused by bacteria. Ceftriaxone reaches therapeutic levels in inflamed meninges and is used in empiric treatment.
Cefotaxime: A third-generation cephalosporin antibiotic with a spectrum similar to ceftriaxone. Cefotaxime is an alternative for meningitis, particularly when ceftriaxone’s neonatal calcium warning matters.
Cephalosporin: A class of beta-lactam antibiotics characterized by a cephalosporin chemical core. Ceftriaxone is a third-generation member of this antibiotic class.
Antimicrobial resistance: The ability of microorganisms to survive exposure to drugs that once inhibited or killed them. Ceftriaxone resistance limits treatment choices and can spread among bacterial populations.
Penicillin-binding proteins: Bacterial enzymes that build and remodel peptidoglycan in the cell wall. Ceftriaxone binds these enzymes and blocks the final stages of cell-wall construction.
Gonorrhea: A sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. Ceftriaxone is the preferred treatment for uncomplicated gonorrhea in current guidelines.
Ceftazidime: A third-generation cephalosporin with strong activity against Pseudomonas aeruginosa. Unlike ceftazidime, ceftriaxone generally lacks reliable antipseudomonal activity.
Third-generation cephalosporin: A cephalosporin subgroup generally distinguished by expanded Gram-negative activity and variable central nervous system penetration. Ceftriaxone is a widely used example of this generation.
Antimicrobial stewardship: Coordinated efforts to use antimicrobial drugs appropriately and preserve their effectiveness. Stewardship discourages unnecessary ceftriaxone use and supports narrowing therapy when results permit.

Linked from 11 pages